purpos
respiratori
infect
common
caus
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
aim
work
studi
etiolog
respiratori
infect
order
assess
use
clinic
analyt
paramet
use
copd
identif
patient
method
includ
patient
period
year
etiolog
respiratori
infect
studi
convent
sputum
pair
serolog
test
atyp
bacteria
viral
diagnost
techniqu
immunochromatographi
immunofluoresc
cell
cultur
molecular
biolog
techniqu
group
patient
four
group
base
pathogen
isol
bacteri
versu
viral
known
etiolog
versu
unknown
etiolog
compar
group
result
pathogen
identifi
patient
pathogen
identifi
sputum
cultur
patient
seroconvers
three
patient
posit
result
viral
techniqu
patient
signific
differ
identifi
etiolog
observ
clinic
analyt
paramet
within
differ
group
costeffect
test
sputum
test
polymeras
chain
reaction
conclus
base
experi
clinic
analyt
paramet
use
etiolog
identif
copd
exacerb
diagnos
copd
exacerb
difficult
convent
sputum
test
bacteri
etiolog
molecular
biolog
techniqu
viral
etiolog
provid
profit
studi
necessari
identifi
respiratori
syndrom
analyt
paramet
use
identifi
etiolog
new
aecopd
case
without
labori
diagnost
techniqu
chronic
obstruct
pulmonari
diseas
copd
associ
signific
morbid
mortal
world
health
organ
estim
rise
fifth
third
lead
caus
death
overal
preval
copd
spain
estim
copd
slow
progress
diseas
patient
experienc
episod
acut
deterior
known
exacerb
increas
frequenc
sever
diseas
progress
caus
acut
exacerb
copd
aecopd
multifactori
half
aecopd
case
attribut
respiratori
infect
exacerb
also
associ
pollut
temperatur
chang
allergen
comorbid
heart
failur
pulmonari
thromboembol
sever
studi
presenc
bacteria
aecopd
associ
purul
sputum
presenc
inflammatori
marker
recent
year
emerg
new
diagnost
techniqu
reveal
relationship
respiratori
virus
addit
etiolog
respiratori
infect
aecopd
patient
differ
accord
geograph
area
current
aecopd
patient
treat
antibiot
first
line
defens
depend
sever
copd
sever
exacerb
emerg
multidrug
resist
increas
econom
spend
antibiot
therapi
numer
studi
assess
benefit
antibiot
treatment
recommend
short
cours
antibiot
treatment
slight
exacerb
similarli
biolog
marker
procalcitonin
propos
marker
antibiot
administr
aecopd
allow
reduct
antibiot
prescript
identif
respiratori
virus
caus
aecopd
may
help
reduc
use
antibiot
therefor
import
find
clinic
analyt
paramet
could
guid
us
identifi
etiolog
new
aecopd
case
especi
consid
labori
diagnost
techniqu
current
use
diagnosi
aim
studi
identifi
etiolog
respiratori
infect
patient
hospit
aecopd
use
differ
diagnost
test
evalu
use
clinic
analyt
paramet
diagnost
process
includ
patient
consecut
admit
hospit
aecopd
april
march
copd
defin
accord
global
initi
chronic
obstruct
pulmonari
diseas
gold
criteria
patient
exhibit
compat
spirometri
measur
smoke
histori
least
ten
packsyear
diagnosi
acut
exacerb
ae
assum
minimum
two
anthonisen
criteria
present
patient
copd
decompens
caus
noninfecti
diseas
exclud
studi
assum
select
patient
present
upper
lower
respiratori
tract
infect
identif
made
base
respiratori
infect
dyspnea
admiss
diagnos
intern
statist
classif
diseas
ninth
revis
clinic
modif
exclud
patient
known
caus
respiratori
failur
differ
infecti
exacerb
heart
failur
pulmonari
thromboembol
pneumonia
final
patient
met
inclus
criteria
none
exclus
criteria
sever
immunosuppress
need
mechan
ventil
admitt
intens
care
unit
arriv
nurs
home
termin
stage
diseas
ask
inform
consent
studi
approv
consorci
sanitari
del
maresm
ethic
committe
hospit
upon
admiss
complet
clinic
histori
physic
exam
perform
patient
demograph
l
ifestyl
characterist
baselin
dyspnea
base
dyspnea
scale
medic
research
council
exacerb
histori
histori
pneumonia
hospit
admiss
previou
year
evalu
contact
famili
member
home
suffer
upper
respiratori
tract
infect
collect
obtain
inform
patient
upper
respiratori
tract
nasal
congest
rhinorrhea
sneez
lower
respiratori
tract
cough
expector
constitut
symptom
dysthermia
fever
chill
asthenia
anorexia
headach
arthromyalgia
impair
conscious
upon
admiss
sever
exacerb
classifi
depend
presenc
respiratori
failur
sever
cyanosi
baselin
dyspnea
deterior
util
accessori
muscl
worsen
blood
ga
level
blood
ph
sever
copd
accord
gold
criteria
copd
prognosi
accord
bodi
mass
airflow
obstruct
dyspnea
exercis
capac
bode
multidimension
index
vital
sign
anthropometr
data
collect
patient
chest
radiograph
taken
rule
pneumonia
baselin
spirometri
measur
collect
patient
treatment
hospit
aecopd
record
submit
manuscript
wwwdovepresscom
baselin
blood
ga
read
complet
cell
blood
count
cbc
basic
biochemistri
read
ast
alt
creatinin
urea
glucos
electrolyt
collect
patient
upon
arriv
emerg
room
routin
blood
analysi
includ
total
protein
protein
profil
perform
follow
day
upon
hospit
admiss
sputum
collect
upon
spontan
expector
convent
manner
without
use
mucolyt
agent
sputa
collect
start
antibiot
treatment
hospit
sputa
cultur
qualiti
criteria
met
sputum
gram
stain
epitheli
cell
polymorphonuclear
leukocyt
sera
collect
patient
admiss
week
initi
collect
second
pair
serolog
passiv
agglutin
techniqu
use
detect
mycoplasma
pneumonia
microimmunofluoresc
use
detect
chlamydia
speci
npl
nasal
exud
collect
hour
admiss
use
viral
detect
differ
techniqu
perform
detail
immunochromatographi
use
rapidli
detect
antigen
influenza
virus
b
respiratori
syncyti
viru
rsv
binaxnow
influenza
b
binaxnow
rsv
test
binax
inc
scarborough
use
accord
manufactur
instruct
immunofluoresc
techniqu
use
detect
influenza
virus
b
adenoviru
parainfluenza
viru
rsv
replic
influenza
virus
b
adenoviru
parainfluenza
rhinoviru
rsv
detect
cell
cultur
determin
presenc
nucleic
acid
influenza
virus
b
rsv
b
parainfluenza
coronavirus
rhinoviru
metapneumoviru
respiratori
rtpcr
kit
pathofind
maastricht
netherland
use
nucleic
acid
respiratori
viru
amplif
test
qiaamp
viral
rna
mini
kit
qiagen
iberia
sl
madrid
spain
use
extract
rna
clinic
sampl
respiratori
rtpcr
kit
pathofind
consist
readytous
solut
contain
primer
taqman
probe
use
accord
condit
set
manufactur
control
visit
perform
one
week
admiss
coincid
hospit
discharg
record
evolut
episod
regard
clinic
symptom
physic
examin
treatment
conjunct
earlier
episod
evalu
identifi
case
treatment
failur
identifi
persist
hemodynam
alter
respiratori
failur
sever
advers
effect
lack
treatment
respons
length
hospit
stay
possibl
complic
also
includ
data
collect
microsoft
access
databas
analyz
use
spss
window
version
ibm
corpor
armonk
ny
qualit
variabl
express
count
percentag
quantit
variabl
express
mean
standard
deviat
interquartil
rang
comparison
mean
perform
use
student
ttest
independ
sampl
mannwhitney
u
test
variabl
meet
criteria
normal
comparison
proport
chisquar
fisher
exact
test
use
case
consid
valu
p
indic
signific
differ
studi
relationship
analyt
clinic
paramet
etiolog
aecopd
three
group
categor
group
contain
patient
viru
detect
diagnost
test
group
includ
patient
exhibit
detect
bacteria
group
contain
patient
unknown
etiolog
studi
period
consecut
patient
admit
hospit
diagnosi
respiratori
infect
dyspnea
accord
guidelin
includ
patient
base
inclus
exclus
criteria
six
patient
clinic
criteria
chronic
bronchiti
spirometri
perform
followup
final
remain
patient
submit
manuscript
wwwdovepresscom
dovepress
dovepress
exclud
followup
spirometri
read
compat
infect
thu
studi
patient
aecopd
probabl
infecti
origin
met
inclus
criteria
caus
acut
decompens
figur
demograph
patient
baselin
characterist
aecopd
present
tabl
patient
hospit
follow
depart
intern
medicin
pneumolog
short
stay
unit
cours
two
year
admiss
peak
coincid
season
variat
exhibit
two
annual
peak
spring
winter
figur
total
pathogen
isol
bacteri
viral
sputum
sampl
survey
gramposit
gramneg
contain
polymorphonuclear
cell
without
bacteria
addit
ziehlneelsen
stain
perform
sampl
neg
result
cultur
result
posit
patient
tabl
higher
number
patient
exhibit
h
influenza
p
aeruginosa
obtain
two
posit
serolog
mycoplasma
pneumonia
one
chlamydia
pneumonia
npl
collect
patient
detect
possibl
viral
etiolog
identifi
posit
result
patient
found
herp
viru
two
patient
detect
herp
viru
attribut
contamin
identifi
posit
result
viral
techniqu
patient
etiolog
agent
identifi
patient
unknown
aecopd
etiolog
assign
patient
bacteri
agent
identifi
etiolog
agent
patient
e
coli
plu
influenza
viru
p
aeruginosa
plu
coronaviru
effici
diagnost
test
shown
tabl
compar
characterist
patient
use
bacteri
viral
isol
assess
clinic
analyt
paramet
aecopd
accord
etiolog
diagnos
signific
differ
observ
except
lymphocyt
count
patient
whose
aecopd
attribut
viru
tabl
obtain
statist
signific
differ
analyt
dataset
patient
known
unknown
etiolog
patient
unknown
etiolog
observ
greater
decreas
ph
baselin
arteri
blood
ga
upon
arriv
emerg
room
well
greater
leukocytosi
increas
heart
rate
tabl
evalu
aecopd
week
hospit
admiss
reveal
clinic
improv
major
patient
treatment
failur
observ
seven
patient
posit
chang
observ
three
patient
treatment
failur
evidenc
worsen
respiratori
failur
three
patient
sever
advers
effect
two
patient
lack
treatment
respons
four
patient
one
patient
die
hospit
prospect
observ
studi
patient
admit
aecopd
vira
includ
followup
period
intend
identifi
infecti
etiolog
copd
exacerb
whether
viral
bacteri
well
describ
clinic
featur
analyt
variabl
use
differenti
caus
exacerb
infecti
caus
identifi
patient
includ
studi
bacteri
etiolog
identifi
patient
viral
infect
observ
patient
two
patient
mix
etiolog
higher
sensit
observ
convent
sputum
analysi
polymeras
chain
reaction
techniqu
pcr
npl
analysi
clinic
laboratori
variabl
evalu
diagnosi
practic
bacteri
viral
etiolog
case
except
rel
lymphocyt
count
lower
group
viral
etiolog
longer
hospit
period
patient
bacteri
infect
attribut
longer
hospit
stay
parenter
treatment
find
multiresist
bacteria
patient
bacteri
etiolog
studi
identifi
clinic
symptom
cold
sore
throat
upon
isol
rhinoviru
even
rhinorrhea
associ
bacteri
etiolog
howev
identifi
clinic
symptom
indic
viral
etiolog
studi
probabl
sampl
size
also
identifi
greater
involv
baselin
arteri
blood
ga
decreas
ph
po
group
unknown
etiolog
well
increas
leukocytosi
heart
rate
could
mean
bronchospasm
compon
contribut
aecopd
within
group
addit
bronchospasm
caus
aecopd
heart
failur
pulmonari
thromboembol
like
exclud
studi
due
fact
select
popul
highli
suspici
respiratori
infect
similarli
exclud
patient
come
residenti
center
patient
admit
hospit
day
prior
current
admiss
patient
transfer
intens
care
unit
order
elimin
hospitalacquir
infect
comprehens
select
patient
may
limit
extern
valid
result
observ
mean
age
year
rang
year
smoke
histori
patient
activ
smoker
probabl
due
high
percentag
men
studi
diagnosi
copd
exacerb
matter
debat
frequent
caus
copd
exacerb
consid
viral
bacteri
bronchial
infect
fact
base
regular
presenc
purul
cough
bacteri
isol
cough
half
patient
exacerb
addit
patient
stabl
copd
evid
bronchial
bacteri
colon
absenc
aeepoc
howev
author
sethi
et
al
demonstr
pathogen
colon
respons
exacerb
haemophilu
infect
addit
bacteri
strain
necessari
elicit
exacerb
identif
bacteri
etiolog
aecopd
primarili
obtain
studi
sputum
obtain
sputum
patient
show
difficulti
obtain
clinic
practic
mix
respiratori
flora
obtain
patient
diagnost
sampl
exhibit
predomin
h
influenza
p
aeruginosa
import
note
patient
sever
copd
exacerb
caus
respiratori
failur
requir
hospit
admiss
h
influenza
p
aeruginosa
detect
mainli
patient
sever
copd
could
explain
inabl
isol
bacteria
pneumococcu
virus
sever
copd
benefit
enterobacteria
p
aeruginosa
routin
use
serolog
use
diagnosi
acut
mycoplasma
pneumonia
chlamydia
infect
point
view
viral
etiolog
pcr
techniqu
perform
bronchial
exud
copd
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
pseudomona
aeruginosa
respiratori
syncyti
viru
studi
result
lower
detect
viru
aecopd
case
littl
evid
influenza
viru
sampl
could
explain
due
fact
influenza
epidem
identifi
studi
period
discrep
data
data
studi
could
also
explain
differ
sampl
techniqu
use
exampl
higher
percentag
obtain
sputum
sampl
npl
sampl
respect
refer
literatur
probabl
could
obtain
better
result
analyz
sputum
rather
obtain
npl
virolog
diagnost
techniqu
even
base
result
obtain
state
viral
infect
could
caus
aecopd
mind
time
prescrib
antibiot
especi
slightli
sick
patient
present
purul
sputum
viral
diseas
season
distribut
therefor
effort
confirm
diagnosi
routin
clinic
practic
note
data
express
number
unless
otherwis
indic
compar
patient
known
diagnost
bacteri
viral
mix
viral
bacteri
mycobacterium
spp
unknown
diagnost
abbrevi
aecopd
acut
chronic
obstruct
pulmonari
diseas
exacerb
crp
creactiv
protein
nat
nucleic
acid
amplif
test
paco
partial
pressur
carbon
dioxid
po
partial
pressur
oxygen
postbd
fev
postbronchodil
forc
expiratori
volum
first
second
sato
satur
oxygen
sd
standard
deviat
ul
unit
per
litr
submit
manuscript
wwwdovepresscom
dovepress
dovepress
reserv
situat
virus
present
commun
otherwis
diagnosi
could
lead
signific
econom
cost
rapid
viral
antigen
detect
immunochromatographi
test
low
diagnost
sensit
use
expens
use
nonepidem
situat
conclus
stress
differenti
etiolog
aecopd
basi
clinic
laboratori
data
difficult
common
clinic
practic
experi
profit
diagnost
test
identifi
possibl
caus
acut
decompens
patient
copd
convent
sputum
test
bacteria
molecular
biolog
techniqu
virus
